Phase 2 Study of ITCA 650 in Subjects With Type 2 Diabetes Mellitus.

Trial Profile

Phase 2 Study of ITCA 650 in Subjects With Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2014

At a glance

  • Drugs Exenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Intarcia Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Oct 2012 Results from weeks 13-24 presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
    • 03 Oct 2012 An analysis of data supporting dose selection for the global phase III programme of exenatide (12- and 24-week outcomes) was reported in an Intarcia Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top